Check out the new and improved FierceBiotech.com

Arsalan Arif, Publisher
Follow me on Twitter and LinkedIn

Dear readers: We've completed a major overhaul of FierceBiotech's website. 

We had one guiding principle with the redesign. It's best captured by Jay Rosen, a prominent press critic and journalism professor at NYU:

"The simplest way to create value in journalism is to save the user time."

Please explore the streamlined new design and let us know if we indeed are saving you time. You, our readers, are some of the busiest executives in the world, so our mission is to give you great content and context in the daily biotechnology news picture as expeditiously as possible. 

I'll discuss in detail the changes we've made in this space Monday. Until then, please take a minute and explore the new site, and then drop me a line with any suggestions or comments you have. After all, we built it for you.

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.